Search
2026 Volume 2
Article Contents
ORIGINAL ARTICLE   Open Access    

Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice

  • #Authors contributed equally: Chuyue Pan, Xu-zhe Zhang, Xiao-wen Xu

More Information
  • Received: 20 April 2026
    Revised: 07 September 2026
    Accepted: 14 September 2026
    Published online: 11 November 2026
    Targetome  2(6),  Article number: e064 (2026)  |  Cite this article
  • Liver fibrosis, induced by viral hepatitis, alcohol abuse, and metabolic dysfunction-associated steatohepatitis (MASH), poses a severe threat to human health worldwide. As liver fibrosis is a critical and potentially reversible stage during liver disease progression, effective therapeutic options for liver fibrosis remain limited. In this study, we identified SNAI1, a multifunctional transcription factor, as a key promoter of liver fibrosis development. By analyzing single-cell RNA sequencing (scRNA-seq), β-galactosidase co-staining with cell-type-specific markers, and SNAI1 expression determined in isolated primary hepatic cells, we demonstrated that SNAI1 is predominantly expressed in hepatic stellate cells (HSCs) and is significantly elevated in fibrotic livers. HSC-specific deletion of Snai1 resulted in markedly improved fibrosis-associated phenotypes induced by CCl4, as evidenced by reduced levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), decreased HSC activation, and collagen deposition in liver tissues. We further found that SNAI1 bound to the promoters of ACTA2 and COL1A1, thereby regulating epigenetic histone acetylation at H3K4, H3K14, and H3K18, which subsequently enhanced HSC activation. Notably, pharmacological inhibition of SNAI1 using the lead compound LFW273 effectively prevented liver fibrosis progression in both CCl4- and methionine-choline-deficient (MCD) diet-induced fibrotic mouse models, with efficacy comparable to the positive control drug, resmetirom. Collectively, our findings reveal a critical regulatory role of SNAI1 in liver fibrosis and establish SNAI1 as a promising drug target for anti-fibrotic therapy.
  • 加载中
  • Supplementary Table S1 Primer set for genotyping.
    Supplementary Table S2 Primer set for RT-PCR.
    Supplementary Table S3 Primer set for ChIP.
    Supplementary Fig. S1 The expression and localization of SNAI1 in liver tissues.
    Supplementary Fig. S2 HSC specific deletion of SNAI1 has no effect on liver physiological functions.
    Supplementary Fig. S3 The modulation of fibrotic gene expression by Snai1 under basal condition.
    Supplementary Fig. S4 LFW273 promotes the degradation of SNAI1.
    Supplementary Fig. S5 LFW273 alleviated the development of CCl4-induced liver fibrosis.
    Supplementary Fig. S6 LFW273 prevented MASH progression in mice fed with MCD diet.
    Supplementary Fig. S7 LFW273 suppressed inflammation in RAW 264.7 macrophages.
  • [1] Kisseleva T, Brenner D. 2021. Molecular and cellular mechanisms of liver fibrosis and its regression. Nature Reviews Gastroenterology & Hepatology 18:151−166 doi: 10.1038/s41575-020-00372-7

    CrossRef   Google Scholar

    [2] Hammerich L, Tacke F. 2023. Hepatic inflammatory responses in liver fibrosis. Nature Reviews Gastroenterology & Hepatology 20:633−646 doi: 10.1038/s41575-023-00807-x

    CrossRef   Google Scholar

    [3] Parola M, Pinzani M. 2019. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Molecular Aspects of Medicine 65:37−55 doi: 10.1016/j.mam.2018.09.002

    CrossRef   Google Scholar

    [4] Friedman SL, Pinzani M. 2022. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 75:473−488 doi: 10.1002/hep.32285

    CrossRef   Google Scholar

    [5] Keam SJ. 2024. Resmetirom: first approval. Drugs 84:729−735 doi: 10.1007/s40265-024-02045-0

    CrossRef   Google Scholar

    [6] Brisnovali NF, Haney C, Goedeke L. 2024. Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis. Trends in Pharmacological Sciences 45:1081−1082 doi: 10.1016/j.tips.2024.08.009

    CrossRef   Google Scholar

    [7] Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, et al. 2026. Semaglutide therapy for metabolic dysfunction – associated steatohepatitis: November 2025 updates to AASLD practice guidance. Hepatology 83:1326−1340 doi: 10.1097/hep.0000000000001608

    CrossRef   Google Scholar

    [8] Noureddin M, Kowdley KV, Odrljin T, Bain G, Zhao J, et al. 2026. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 407:794−804 doi: 10.1016/s0140-6736(25)02276-7

    CrossRef   Google Scholar

    [9] Ni T, Li XY, Lu N, An T, Liu ZP, et al. 2016. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nature Cell Biology 18:1221−1232 doi: 10.1038/ncb3425

    CrossRef   Google Scholar

    [10] Wu ZQ, Rowe RG, Lim KC, Lin Y, Willis A, et al. 2014. A Snail1/Notch1 signalling axis controls embryonic vascular development. Nature Communications 5:3998 doi: 10.1038/ncomms4998

    CrossRef   Google Scholar

    [11] Grande MT, Sánchez-Laorden B, López-Blau C, De Frutos CA, Boutet A, et al. 2015. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nature Medicine 21:989−997 doi: 10.1038/nm.3901

    CrossRef   Google Scholar

    [12] Manetti M, Romano E, Rosa I, Guiducci S, Bellando-Randone S, et al. 2017. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases 76:924−934 doi: 10.1136/annrheumdis-2016-210229

    CrossRef   Google Scholar

    [13] Jayachandran A, Königshoff M, Yu H, Rupniewska E, Hecker M, et al. 2009. SNAI transcription factors mediate epithelial-mesenchymal transition in lung fibrosis. Thorax 64:1053−1061 doi: 10.1136/thx.2009.121798

    CrossRef   Google Scholar

    [14] Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, et al. 2011. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53:1685−1695 doi: 10.1002/hep.24206

    CrossRef   Google Scholar

    [15] Rowe RG, Lin Y, Shimizu-Hirota R, Hanada S, Neilson EG, et al. 2011. Hepatocyte-derived Snail1 propagates liver fibrosis progression. Molecular and Cellular Biology 31:2392−2403 doi: 10.1128/mcb.01218-10

    CrossRef   Google Scholar

    [16] Wang P, Kang Q, Wu WS, Rui L. 2024. Hepatic Snai1 and Snai2 promote liver regeneration and suppress liver fibrosis in mice. Cell Reports 43:113875 doi: 10.1016/j.celrep.2024.113875

    CrossRef   Google Scholar

    [17] Bao L, Chu Y, Kang H. 2023. SNAI1-activated long non-coding RNA LINC01711 promotes hepatic fibrosis cell proliferation and migration by regulating XYLT1. Genomics 115:110597 doi: 10.1016/j.ygeno.2023.110597

    CrossRef   Google Scholar

    [18] Tan S, Lu Y, Xu M, Huang X, Liu H, et al. 2019. β-Arrestin1 enhances liver fibrosis through autophagy‐mediated Snail signaling. The FASEB Journal 33:2000−2016 doi: 10.1096/fj.201800828RR

    CrossRef   Google Scholar

    [19] Sugimoto A, Saito Y, Wang G, Sun Q, Yin C, et al. 2025. Hepatic stellate cells control liver zonation, size and functions via R-spondin 3. Nature 640:752−761 doi: 10.1038/s41586-025-08677-w

    CrossRef   Google Scholar

    [20] Trépo E, Goossens N, Fujiwara N, Song WM, Colaprico A, et al. 2018. Combination of gene expression signature and model for end-stage liver disease score predicts survival of patients with severe alcoholic hepatitis. Gastroenterology 154:965−975 doi: 10.1053/j.gastro.2017.10.048

    CrossRef   Google Scholar

    [21] Jeong BK, Choi WI, Choi W, Moon J, Lee WH, et al. 2024. A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma. Nature Communications 15:6506 doi: 10.1038/s41467-024-50660-y

    CrossRef   Google Scholar

    [22] Steixner-Kumar AA, Santacruz D, Geiger T, Rust W, Böttner D, et al. 2025. Single-cell landscape of peripheral immune cells in MASLD/MASH. Hepatology Communications 9:e0643 doi: 10.1097/hc9.0000000000000643

    CrossRef   Google Scholar

    [23] Uchinami H, Seki E, Brenner DA, D'Armiento J. 2006. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44:420−429 doi: 10.1002/hep.21268

    CrossRef   Google Scholar

    [24] Wang L, Mazagova M, Pan C, Yang S, Brandl K, et al. 2019. YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. Proceedings of the National Academy of Sciences of the United States of America 116:15184−15193 doi: 10.1073/pnas.1904360116

    CrossRef   Google Scholar

    [25] Li ZW, Ruan B, Yang PJ, Liu JJ, Song P, et al. 2023. Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells. Signal Transduction and Targeted Therapy 8:344 doi: 10.1038/s41392-023-01621-2

    CrossRef   Google Scholar

    [26] Mederacke I, Dapito DH, Affò S, Uchinami H, Schwabe RF. 2015. High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nature Protocols 10:305−315 doi: 10.1038/nprot.2015.017

    CrossRef   Google Scholar

    [27] Pan C, Liu J, Gao Y, Yang M, Hu H, et al. 2023. Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. Cell Metabolism 35:2231−2249. e7 doi: 10.1016/j.cmet.2023.10.018

    CrossRef   Google Scholar

    [28] Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, et al. 2020. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacologica Sinica 41:336−347 doi: 10.1038/s41401-019-0310-0

    CrossRef   Google Scholar

    [29] Ren B, Li Y, Di L, Cheng R, Liu L, et al. 2024. A naturally derived small molecule compound suppresses tumor growth and metastasis in mice by relieving p53-dependent repression of CDK2/Rb signaling and the Snail-driven EMT. Chinese Journal of Natural Medicines 22:112−126 doi: 10.1016/s1875-5364(24)60550-9

    CrossRef   Google Scholar

    [30] Ren BX, Zeng ZL, Deng L, Hu JM, Chen MZ, et al. 2025. Genetic and pharmacological targeting of Snail inhibits atherosclerosis by relieving intraplaque endothelium dysfunction and associated inflammation. Acta Pharmacologica Sinica 46:2196−2212 doi: 10.1038/s41401-025-01519-5

    CrossRef   Google Scholar

    [31] Geng F, Zhong Y, Su H, Lefai E, Magaki S, et al. 2023. SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells. Cell Reports 42:112790 doi: 10.1016/j.celrep.2023.112790

    CrossRef   Google Scholar

    [32] Tao J, Wu Z, Liang Y, Wang J, Tang M, et al. 2025. Lhx2 specifically expressed in HSCs promotes liver regeneration and inhibits liver fibrosis. Hepatology 82:683−701 doi: 10.1097/hep.0000000000001201

    CrossRef   Google Scholar

    [33] Schwabe RF, Brenner DA. 2025. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease. Nature Reviews Gastroenterology & Hepatology 22:481−499 doi: 10.1038/s41575-025-01068-6

    CrossRef   Google Scholar

    [34] Yang W, He H, Wang T, Su N, Zhang F, et al. 2021. Single-cell transcriptomic analysis reveals a hepatic stellate cell–activation roadmap and myofibroblast origin during liver fibrosis in mice. Hepatology 74:2774−2790 doi: 10.1002/hep.31987

    CrossRef   Google Scholar

    [35] Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. 2000. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology 2:76−83 doi: 10.1038/35000025

    CrossRef   Google Scholar

    [36] Singh D, Deshmukh RK, Das A. 2021. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells. Cellular Signalling 87:110151 doi: 10.1016/j.cellsig.2021.110151

    CrossRef   Google Scholar

    [37] Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, et al. 2004. Peroxisome proliferator-activated receptor γ induces a phenotypic switch from activated to quiescent hepatic stellate cells. Journal of Biological Chemistry 279:11392−11401 doi: 10.1074/jbc.M310284200

    CrossRef   Google Scholar

    [38] Sharvit E, Abramovitch S, Reif S, Bruck R. 2013. Amplified inhibition of stellate cell activation pathways by PPAR-γ, RAR and RXR agonists. PLoS One 8:e76541 doi: 10.1371/journal.pone.0076541

    CrossRef   Google Scholar

    [39] Man S, Deng Y, Ma Y, Fu J, Bao H, et al. 2023. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5. 7 million adults in China. Gastroenterology 165:1025−1040 doi: 10.1053/j.gastro.2023.05.053

    CrossRef   Google Scholar

    [40] Zhao M, Wang L, Wang M, Zhou S, Lu Y, et al. 2022. Targeting fibrosis: mechanisms and clinical trials. Signal Transduction and Targeted Therapy 7:206 doi: 10.1038/s41392-022-01070-3

    CrossRef   Google Scholar

    [41] Parola M, Pinzani M. 2024. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies. Molecular Aspects of Medicine 95:101231 doi: 10.1016/j.mam.2023.101231

    CrossRef   Google Scholar

    [42] Kumar V, Xin X, Ma J, Tan C, Osna N, et al. 2021. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Advanced Drug Delivery Reviews 176:113888 doi: 10.1016/j.addr.2021.113888

    CrossRef   Google Scholar

    [43] Bao Z, Zeng W, Zhang D, Wang L, Deng X, et al. 2022. SNAIL induces EMT and lung metastasis of tumours secreting CXCL2 to promote the invasion of M2-type immunosuppressed macrophages in colorectal cancer. International Journal of Biological Sciences 18:2867−2881 doi: 10.7150/ijbs.66854

    CrossRef   Google Scholar

    [44] Carmichael CL, Wang J, Nguyen T, Kolawole O, Benyoucef A, et al. 2020. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood 136:957−973 doi: 10.1182/blood.2019002548

    CrossRef   Google Scholar

    [45] Elia I, Realini G, Di Mauro V, Borghi S, Bottoni L, et al. 2022. SNAI1 is upregulated during muscle regeneration and represses FGF21 and ATF3 expression by directly binding their promoters. The FASEB Journal 36:e22401 doi: 10.1096/fj.202200215R

    CrossRef   Google Scholar

    [46] Yang F, Li H, Li Y, Hao Y, Wang C, et al. 2021. Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis. International Immunopharmacology 99:108051 doi: 10.1016/j.intimp.2021.108051

    CrossRef   Google Scholar

    [47] Lan R, Lin J, Chen S, Lu Z, Gong Y, et al. 2025. Communication initiated by hepatocytes: the driver of HSC activation and liver fibrosis. Hepatology Communications 9:e0753 doi: 10.1097/hc9.0000000000000753

    CrossRef   Google Scholar

    [48] Gupta G, Khadem F, Uzonna JE. 2019. Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity. Cytokine 124:154542 doi: 10.1016/j.cyto.2018.09.004

    CrossRef   Google Scholar

    [49] Qian H, Deng X, Huang ZW, Wei J, Ding CH, et al. 2015. An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells. Cell Research 25:930−945 doi: 10.1038/cr.2015.84

    CrossRef   Google Scholar

    [50] Tsuchida T, Friedman SL. 2017. Mechanisms of hepatic stellate cell activation. Nature Reviews Gastroenterology & Hepatology 14:397−411 doi: 10.1038/nrgastro.2017.38

    CrossRef   Google Scholar

    [51] Felli E, Nulan Y, Ortega-Ribera M, Fernández-Iglesias A, Gracia-Sancho J. 2026. The role of liver sinusoidal endothelial cells in liver diseases: key players in health and pathology. Journal of Hepatology 84:655−672 doi: 10.1016/j.jhep.2025.10.017

    CrossRef   Google Scholar

    [52] Zhou Y, Zhao D, Ma Q, Xu J, Cai Y, et al. 2025. Endothelial adenosine receptor 2A loss alleviates diabetic vascular calcification by blocking CREB1-SNAI1-driven EndMT. Pharmacological Research 221:107981 doi: 10.1016/j.phrs.2025.107981

    CrossRef   Google Scholar

    [53] Xu X, Tan X, Tampe B, Sanchez E, Zeisberg M, et al. 2015. Snail is a direct target of hypoxia-inducible factor 1α (HIF1α) in hypoxia-induced endothelial to mesenchymal transition of human coronary endothelial cells. Journal of Biological Chemistry 290:16653−16664 doi: 10.1074/jbc.M115.636944

    CrossRef   Google Scholar

    [54] Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, et al. 2008. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48:770−781 doi: 10.1002/hep.22423

    CrossRef   Google Scholar

    [55] Cai Y, Li H, Liu M, Pei Y, Zheng J, et al. 2018. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology 68:48−61 doi: 10.1002/hep.29777

    CrossRef   Google Scholar

    [56] Gallage S, Avila JEB, Ramadori P, Focaccia E, Rahbari M, et al. 2022. A researcher’s guide to preclinical mouse NASH models. Nature Metabolism 4:1632−1649 doi: 10.1038/s42255-022-00700-y

    CrossRef   Google Scholar

  • Cite this article

    Pan C, Zhang XZ, Xu XW, Zeng ZL, Weiss SJ, et al. 2026. Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice. Targetome 2(6): e064 doi: 10.48130/targetome-0026-0060
    Pan C, Zhang XZ, Xu XW, Zeng ZL, Weiss SJ, et al. 2026. Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice. Targetome 2(6): e064 doi: 10.48130/targetome-0026-0060

Figures(7)

Article Metrics

Article views(335) PDF downloads(46)

ORIGINAL ARTICLE   Open Access    

Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice

Targetome  2,  Article number: e064  (2026)  |  Cite this article

Abstract: Liver fibrosis, induced by viral hepatitis, alcohol abuse, and metabolic dysfunction-associated steatohepatitis (MASH), poses a severe threat to human health worldwide. As liver fibrosis is a critical and potentially reversible stage during liver disease progression, effective therapeutic options for liver fibrosis remain limited. In this study, we identified SNAI1, a multifunctional transcription factor, as a key promoter of liver fibrosis development. By analyzing single-cell RNA sequencing (scRNA-seq), β-galactosidase co-staining with cell-type-specific markers, and SNAI1 expression determined in isolated primary hepatic cells, we demonstrated that SNAI1 is predominantly expressed in hepatic stellate cells (HSCs) and is significantly elevated in fibrotic livers. HSC-specific deletion of Snai1 resulted in markedly improved fibrosis-associated phenotypes induced by CCl4, as evidenced by reduced levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), decreased HSC activation, and collagen deposition in liver tissues. We further found that SNAI1 bound to the promoters of ACTA2 and COL1A1, thereby regulating epigenetic histone acetylation at H3K4, H3K14, and H3K18, which subsequently enhanced HSC activation. Notably, pharmacological inhibition of SNAI1 using the lead compound LFW273 effectively prevented liver fibrosis progression in both CCl4- and methionine-choline-deficient (MCD) diet-induced fibrotic mouse models, with efficacy comparable to the positive control drug, resmetirom. Collectively, our findings reveal a critical regulatory role of SNAI1 in liver fibrosis and establish SNAI1 as a promising drug target for anti-fibrotic therapy.

    • Liver fibrosis is a pathological consequence of chronic liver injury and inflammation, usually caused by viral hepatitis, alcohol-related liver disease (ALD), and metabolic dysfunction-associated steatohepatitis (MASH)[1,2]. However, liver fibrosis, as the final reversible stage before progression to liver cirrhosis and hepatocellular carcinoma (HCC), faces a great challenge in therapy[3,4]. The discovery of anti-fibrotic targets has advanced rapidly in recent decades, particularly for MASH-related fibrosis. Not only have semaglutide and resmetirom been approved by the US Food and Drug Administration (FDA), but other FGF21 analogues, such as efimosfermin alfa, are also currently under phase III clinical trials[5−8]. Admittedly, their effects on resolving fibrosis are moderate, and long-term effects require further evaluation. Elucidating the molecular mechanism of fibrosis progression and potential pharmacological therapeutic targets for liver fibrosis is thus urgently needed.

      SNAI1 is one of the members of zinc-finger (ZF) transcription factors that function as a regulator of epithelial-to-mesenchymal transition (EMT) during embryonic development and tumor metastasis[9,10]. SNAI1 has been reported to promote the progression of renal fibrosis, dermal fibrosis, and pulmonary fibrosis by enhancing EMT[11−13]. However, lineage tracing has demonstrated that neither hepatocytes nor cholangiocytes undergo EMT in several murine models of hepatic fibrosis[14], which differs from other fibrotic diseases. It is hepatic stellate cells (HSCs) that are the most critical contributors during liver fibrosis; they reside in the space of Disse under physiological conditions and are activated to secrete extracellular matrix (ECM) after liver injury[1]. Thus, targeting HSC activation is a key strategy for the development of anti-fibrotic drugs. Previous studies on hepatic SNAI1 have primarily focused on hepatocytes[15,16], or have utilized it as one of the indicators of liver fibrosis[17,18]. Therefore, the systemic functions and downstream mechanisms of SNAI1 in HSCs, as well as its therapeutic potential as an anti-fibrotic drug target, remain to be investigated.

      In this study, by integrating scRNA-seq, primary cell isolation, and Snai1-LacZ reporter mice, we demonstrated that SNAI1 is predominantly expressed in HSCs rather than in hepatocytes. HSC-specific Snai1 knockdown showed decreased HSC activation and collagen production, thereby attenuating the progression of liver fibrosis. Mechanistically, we further identified that SNAI1 directly regulates the transcription of the two most representative fibrotic marker genes (ACTA2 and COL1A1) by binding to their promoters. Finally, we evaluated the druggability of SNAI1 using a small-molecule inhibitor and validated its therapeutic efficacy in CCl4-induced and MASH-associated fibrosis. Overall, these findings provide insights into the HSC-specific role and mechanism of SNAI1 in liver fibrosis, and suggest its potential as a viable anti-fibrotic drug target.

    • The human SNAI1 gene expression and location in various liver cell types were analyzed using public scRNA-seq data from the Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo). The GSE256398 database includes data from three patients with metabolic dysfunction-associated steatotic liver disease (MASLD), four patients with MASH-associated fibrosis, four patients with MASH-associated cirrhosis, and six healthy controls[19]. Healthy individuals and non-fibrotic MASLD patients served as the Control group, and patients with MASH-associated fibrosis and cirrhosis were divided into the Fibrosis group. Raw scRNA-seq data were analyzed using the R package Seurat. Quality control retained cells with 200–6,000 detected genes, < 10% mitochondrial transcripts, and < 25,000 UMIs. Putative doublets were filtered out using scDblFinder. Data were log-normalized, and the top 2,000 highly variable genes were used for principal component analysis (PCA). Batch effects were integrated using Harmony across the first 15 principal components. Cells were clustered via the Louvain algorithm (resolution = 0.6), visualized using UMAP, and manually annotated into major liver lineages (HEP, ECS, EPS, HSCS, NK/T, B, DC) based on canonical marker genes. Differences in mean SNAI1 expression between groups were evaluated using the two-sided Wilcoxon rank-sum test, with P < 0.05 considered statistically significant.

    • Clinical datasets were acquired from GSE94417, GSE246221, and GSE267031. GSE94417 database included 109 individuals with non-fibrotic disease and 67 patients with hepatitis or cirrhosis[20]. Twenty-eight patients with MASLD and metabolic associated fatty liver disease (MAFLD)/MASH patients from databases GSE246221 and GSE267031, respectively, were also included in this study[21,22].

    • Mice were housed under standard specific-pathogen-free (SPF) conditions with free access to food and water; the temperature was maintained at 25 °C under a regular 12-h light/dark cycle. All animal procedures were approved by the institutional Animal Care and Use Committee of China Pharmaceutical University.

      C57BL/6J wild-type mice (WT; male, 8–10-week-old) were purchased from Jiangsu Huachuang SinoPharmaTech Co., Ltd (Nanjing, China). Snai1-floxed (Snai1flox/flox) mice and mice with Snai1-LacZ knock-in alleles have been described previously[9]. Lrat-Cre transgenic mice (T006205) were obtained from GemPharmatech (Nanjing, China) and crossed with Snai1flox/flox mice to generate Snai1ΔHSC mice. All the primers for mouse genotyping were listed in Supplementary Table S1.

      For CCl4-induced liver fibrosis, age-matched mice (C57BL/6J, male, 8-week-old) were intraperitoneally injected with 10% CCl4 (in olive oil; 10 mL·g−1) or olive oil twice a week for 4 weeks. Bile duct ligation (BDL) surgery was performed as described before[23]. Briefly, mice were anesthetized and subjected to a 1 cm laparotomy, and the bile duct was exposed and ligated with 6−0 silk sutures. Two ligatures were placed in the proximal and distal portions of the bile duct, respectively, and then the bile duct was cut between the ligatures. The abdomen was closed in layers, and mice were taken care of to maintain body temperature until they were awake. Mice were sacrificed at the appropriate time to collect liver tissues. MCD diet (A02082002BR, research diets) was used to feed WT (C57BL/6J, male, 10-week-old) mice for 6 weeks to induce MASH-associated liver fibrosis. For pharmacological inhibition of SNAI1, LFW273 was intragastrically administered at the dose of 100 mg·kg−1, and resmetirom was administered with 3 mg·kg−1 for oral administration.

    • HEK293 (SCSP-502), LX2 (SCSP-527), and RAW 264.7 (SCSP-5036) cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM supplemented with 1% antibiotics and FBS (10% for HEK293 and RAW 264.7; 2% for LX2). All cells were cultured at 37 °C with 5% CO2 supplied.

    • Primary hepatocytes and nonparenchymal cells (NPCs) were isolated as described in previous studies[23,24]. Primary HSCs, Kupffer cells (KCs), and liver sinusoidal endothelial cells (LSECs) were isolated from CCl4-induced WT and Snai1ΔHSC mouse livers. Briefly, anaesthetized mice were perfused with buffer SC-1 (137 mmol·L−1 NaCl, 5.4 mmol·L−1 KCl, 0.7 mmol·L−1 NaH2PO4·H2O, 0.85 mmol·L−1 Na2HPO4, 10 mmol·L−1 HEPES, 2 mmol·L−1 NaHCO3, 0.5 mmol·L−1 EGTA, 5 mmol·L−1 glucose), SC-2-I (SC-1 without EGTA but added 3.8 mmol·L−1 CaCl2·H2O) (containing Pronase E), and SC-2-II (containing collagenase D) for 5 min each. Digested liver was transferred into cold SC-2 buffer (without collagenase) and then gently suspended. The cell suspension was mixed with another digest buffer (SC-2 containing Pronase E, Collagenase D, and DNase I) for 20 min at 37 °C. The mixture was filtered through 70 μm cell strainers and centrifuged at 500 r·min−1 for 1 min. The precipitate was hepatocytes, and the supernatant contained NPCs. After centrifugation (2,200 r·min−1, 8 min), NPCs were mixed with Nycodenz solution (10%) and were carefully layered onto the 15% Nycodenz solution for 30-min density gradient centrifugation. The first layer under clear buffer was HSCs, and the second layer was cells containing KCs and LSECs. The second layer was plated on a plastic dish for 20 min to collect KCs. CD146 beads (Miltenyi Biotec, 130−092−007) were used to obtain purified LSECs[25]. HSCs, KCs, and LSECs isolated from every three mice were combined into one sample for subsequent measurements.

      Primary HSCs for RNA-seq were isolated from individual mice as described before[26]. Briefly, the liver was perfused with SC-1 for 2 min, followed by SC-2 with Pronase E for 5 min, and then SC-2 with Collagenase D for 7 min, at a flow rate of 5 mL·min−1. The digested liver was suspended and transferred to 50 mL of SC-2 (containing Pronase E, Collagenase D, and 1% DNase I) for another 25 min digestion. The cells were filtered through 70 μm cell strainers and centrifuged at 580 × g for 10 min, and then resuspended in Nycodenz solution at a final concentration of 10%. Clear GBSS/B buffer was carefully layered onto the cell-Nycodenz mixture. Centrifugation was then performed at 1,380 × g for 17 min without braking, and HSCs were collected at the interface between GBSS/B and Nycodenz.

    • H&E and Sirius red staining of liver sections were performed as described previously[27]. Masson staining of liver sections was conducted based on the manufacturer’s protocol (Servicebio, G1006). Frozen liver sections were used for Oil Red O staining[28].

    • Frozen livers were sectioned and then treated with the Senescence β-Galactosidase Staining Kit (Beyotime, China). Briefly, after three PBS rinses and 15 min of fixation, liver sections were dipped in the working solution (Buffer A + B + C + X-Gal solution according to the instructions of the kit) at 37 °C overnight. The images were acquired by microscope (Olympus IX73, Japan) the next day[9].

    • As described in our previous study[27,29], paraffin-embedded sections were deparaffinized and rehydrated by rinsing in xylene and ethyl alcohol. Antigen retrieval was performed using an antigen unmasking solution (Vector Laboratories), and 0.3% Triton X-100 was used for permeabilization. After being immersed in 1% H2O2 for 30 min, sections were blocked with 5% goat serum in 0.5% bovine serum albumin for another 30 min. Primary antibodies anti-α-SMA (Abcam, ab5694), anti-COL1A1 (Huabio, ET1609), anti-KI67 (Abcam, ab15580), and anti-p-H3 (Cell Signaling Technology, 9701s) were incubated overnight at 4 °C. The next day, the sections were incubated with biotin-labeled secondary antibody and ABC solution (Vector Laboratories) for 30 min, and then followed by DAB solution (Vector Laboratories) staining. The nuclei were marked by hematoxylin.

    • LX2 cells were seeded on glass coverslips and treated with TGF-β (10 μmol·L−1) and LFW273 (5 or 10 μmol·L−1) for 48 h. Cells were then fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X. After three PBS rinses and 30 min of blocking, primary antibody anti-COL1A1 (Huabio, ET1609, 1 : 200) and corresponding secondary antibody Alexa Fluor 488 (Invitrogen, A-11008) were used for staining. Images were acquired by a confocal laser scanning microscope (Carl Zeiss, LSM900). The quantification of COL1A1 in LX2 cells was calculated as integrated intensity/cell number.

    • Serum was collected for liver function tests by Wuhan Servicebio Technology Co., Ltd, including ALT, AST, total bile acid level (TBA), γ-glutamyl transpeptidase level (γ-GT), direct bilirubin level (DBIL), and total bilirubin level (TBIL).

    • Serum and hepatic TG and TC levels were measured according to the manufacturer’s protocol (Nanjing Jiancheng, A110-1-1, A111-1-1).

    • Real-time PCR was conducted as described in our previous studies[9,27]. The primer sequences are shown in Supplementary Table S2.

    • The RNA-sequencing experiments of primary HSCs and LX2 cells and their downstream data analyses were performed as previously described[27]. Original RNA-seq data were deposited in the GEO database with Accession No. GEO: GSE329196.

    • Total protein was extracted with RIPA lysis buffer (Thermo, 89901) and supplemented with protease and phosphatase inhibitor. Proteins were detected by their specific primary antibodies and visualized on film using HRP-conjugated secondary antibodies. Primary antibodies SNAI1 (Cell Signaling Technology, 3879S), SLUG (Abcam, ab51772), α-SMA (Abcam, ab5694), COL1A1 (Huabio, ET1609), β-actin (Santa Cruz Biotechnology, sc47778), and β-tubulin (Santa Cruz Biotechnology, sc5274) were used.

    • As described in previous studies[30], cells were fixed in 1% formaldehyde for 10 min and incubated in 1.25 mol·L−1 glycine for 5 min at room temperature. After washing with cold PBS twice, cells were lysed in IP lysis buffer (50 mmol·L−1 Tris-HCl, 150 mmol·L−1 NaCl, 1 mmol·L−1 EDTA, 1% NP-40, 0.05% SDS, pH 7.4), supplemented with protease inhibitor cocktail for 20 min on ice. The cell lysates were sonicated to obtain DNA fragments of approximately 200−1,000 bp in length. The supernatants were pre-cleared with protein A/G beads and treated with salmon sperm DNA to block nonspecific binding (Thermo Fisher, 15632011) at 4 °C for 1 h. For the sheared chromatin, 10% of the lysate was used as input control, and the rest was incubated overnight with the following antibodies against Flag (Sigma, F3165), acetyl-histone H3 (K4; Abcam, ab176799), acetyl-histone H3 (K18; Cell Signaling, 9675), acetyl-histone H3 (K14; Cell Signaling, 7627), tri-methyl-histone H3 (K27; Cell Signaling, 9377), or Rabbit IgG (Abcam, ab172730) with rotation at 4 °C, followed by an additional incubation using precleared protein A/G beads for 1 h at 4 °C. After standing for 10 min and centrifugation, the chromatins bound to the beads were subjected to sequential washes: once with low-salt wash buffer, once with high-salt wash buffer, and twice with TE buffer. Subsequently, elution was performed twice using elution buffer (1% SDS, 0.1 mol·L−1 NaHCO3), and the DNA-protein complexes were then subjected to an overnight incubation at 65 °C with 0.2 mol·L−1 NaCl. After incubating with RNase A for another 30 min at 37 °C the next day, proteinase K (Thermo Fisher, AM2548) was subsequently added, and the mixture was incubated at 45 °C for 2 h. Purification of the bound DNA was performed with a kit (Sigma-Aldrich, NA1020) following the manufacturer’s protocol, and was subsequently analyzed by PCR. Primers were designed to span the proximal, middle, and distal regions of the promoter (−2 kb to 0), and representative images are shown in corresponding figures. Primer sequences are provided in Supplementary Table S3.

    • The ~2.0 kb fragment of the human COL1A1 promoter (−2,000–0) and the ~2.1 kb fragment of the human ACTA2 promoter (−2000−0) were synthesized by GenScript and subcloned into the pGL3-basic luciferase reporter vector. Control or SNAI1-overexpressing LX2 cells were transfected with COL1A1 or ACTA2 reporter constructs and the pRL-TK Renilla luciferase control construct. Dual-luciferase reporter assays were performed according to the manufacturer’s instructions (YEASEN, 11402-E).

    • Cells were fixed with 4% paraformaldehyde and stained by incubating cells with 0.5 mmol·L−1 BODIPY 493/503 (Life Technologies) for 30 min[31]. The images were acquired by a confocal laser scanning microscope (Carl Zeiss LSM900). The quantification of BODIPY staining was calculated as integrated intensity/cell number.

    • All data in this study are presented as mean ± SEM and were graphed using GraphPad PRISM 9. A two-tailed Student's t-test was used for statistical analysis of the two-group comparisons; ordinary one-way ANOVA with Dunnett's multiple comparisons test and one-way ANOVA with Newman–Keuls multiple comparisons test were used for the statistical analysis of differences between multiple groups. A P value < 0.05 was considered statistically significant.

    • To explore the role of SNAI1 in liver fibrosis, we first examined its expression in healthy and fibrotic livers. Analysis of a public microarray dataset (GEO: GSE94417) revealed that fibrotic tissues exhibited higher SNAI1 expression compared with non-fibrotic individuals (Fig. 1a). Additionally, we found that the expression of SNAI1 was positively correlated with the expression of fibrosis-associated genes, including ACTA2, COL1A1, and COL3A1 in patients with MAFLD or MASH (GEO: GSE246221 and GSE267031) (Fig. 1b; Supplementary Fig. S1a and S1b). In order to investigate which cell types express SNAI1, we subsequently analyzed single-cell transcriptomic data from livers of healthy individuals and patients with liver cirrhosis (GSE256398). These analyses showed that SNAI1 was mainly expressed in HSCs and endothelial cells (ECs) (Fig. 1c); however, under fibrotic conditions, SNAI1 expression was specifically upregulated in HSCs (Fig. 1d). Moreover, similar results were observed in mouse models. CCl4 injection and BDL surgery were used to induce liver fibrosis in Snai1-LacZ mice, in which β-gal expression reflects the SNAI1 levels in liver tissues[9] (Fig. 1e and f; Supplementary Fig. S1c and S1d). SNAI1 expression was markedly increased in CCl4-treated mice compared with mice injected with olive oil (Control) (Fig. 1e and f). Notably, the co-staining revealed that β-gal signals colocalized with HSC markers (α-SMA or COL1A1) but not with KC marker F4/80 or the LSEC marker CD31 (Fig. 1e and f; Supplementary Fig. S1c and S1d). Furthermore, we confirmed that SNAI1 was predominantly expressed in HSCs using real-time PCR and immunoblotting on isolated primary mouse liver cells (Fig. 1g and h; Supplementary Fig. S1e). Hepatocytes barely expressed SNAI1, whereas HSCs exhibited the highest expression level of SNAI1 among all liver cell types. Consistently, SNAI1 expression in HSCs was upregulated during fibrosis progression.

      Figure 1. 

      SNAI1 expression in HSCs was upregulated during the progression of liver fibrosis. (a) Relative mRNA level of SNAI1 acquired from the Gene Expression Omnibus (GSE94417) in livers from healthy controls or patients with cirrhosis. (b) Correlation of relative SNAI1 expression with ACTA2 and COL1A1 in patients with MASH. Genetic data acquired from GSE246221 and GSE267031, respectively. (c) Single-cell transcriptome analysis of data from GSE256398; UMAP visualization of liver cell clusters based on human scRNA sequencing (left). Red dots represent the expression of SNAI1 (right). (d) Mean SNAI1 expression level in endothelial cells (ECs) and HSCs. (e) Representative images of Masson staining, β-gal staining, and β-gal/α-SMA co-staining in mice injected with oil (Control) and CCl4. Arrows indicate the positive area of β-gal/α-SMA. Scale bar: 50 μm. (f) Quantification of the positive area in Fig. 1e. Primary hepatocytes, HSCs, KCs, and LSECs were isolated from liver tissues in mice subjected to oil or CCl4 for 4 weeks. (g) mRNA levels of Snai1 in hepatocytes and HSCs. (h) Protein levels of SNAI1 in hepatocytes, HSCs, KCs, and LSECs. Data are presented as mean ± SEM. P < 0.05 indicates a significant difference. All data were analyzed by two-tailed Student’s t-test except data in (d) using Wilcoxon Mann–Whitney test.

    • To elucidate the functional relevance of SNAI1 in HSCs during liver fibrosis in vivo, we generated HSC-specific Snai1-deficient mice by crossing Lrat-Cre mice with Snai1-floxed mice (Fig. 2a; Supplementary Fig. S2a). As expected, the mRNA and protein levels of SNAI1 in primary HSCs isolated from mouse livers were significantly reduced in Snai1ΔHSC mice compared with Snai1flox/flox mice (Fig. 2b). Having confirmed that Snai1 deletion in HSCs did not affect the baseline liver histology and functions (Supplementary Fig. S2b and S2c), we proceeded to investigate whether Snai1 deficiency in HSCs was able to protect against CCl4-induced liver fibrosis (Fig. 2a). As shown in Fig. 2c, Snai1 HSC-deficient mice had lower levels of ALT and AST relative to control mice after CCl4 injection, suggesting attenuated liver injury. Moreover, Snai1ΔHSC mice exhibited lower collagen deposition and reduced HSC activation, as assessed by Masson staining, Sirius red staining, and anti-α-SMA immunohistochemical staining or immunoblotting, respectively (Fig. 2d−f). Consistently, CCl4-treated Snai1ΔHSC mice showed significantly decreased expression of genes involved in HSC activation and collagen homeostasis, such as Acta2, Col1a1, Col3a1, Col6a3, Timp1, Fap, and Mmp2 (Fig. 2g). In addition, the expressions of genes encoding pro-inflammatory cytokines and chemokines (Tnf, Ccl5, and Ccl2) were downregulated in Snai1ΔHSC mouse livers (Fig. 2g), whereas expressions of Col1a2, Timp2, Tgfb1-3, Il1b, and Il6 remained unchanged (Supplementary Fig. S2d). Given that promoting liver regeneration is a promising strategy for fibrosis treatment[32], we examined hepatocyte proliferation and observed a slight increase in Snai1ΔHSC mice (Fig. 2h and i), supporting that HSC-specific Snai1 deletion attenuates hepatic fibrosis in part by promoting liver regeneration.

      Figure 2. 

      HSC-specific deficiency of Snai1 protected mice from CCl4-induced liver fibrosis. (a) Schematic of the Snai1ΔHSC mouse generation strategy and 4-week CCl4-induced fibrotic mouse model. (b) SNAI1 protein and mRNA levels of primary HSCs were isolated from Snai1flox/flox and Snai1ΔHSC mouse liver. Snai1flox/flox and Snai1ΔHSC mice were injected with CCl4 twice a week for 4 weeks (n = 6 for Snai1flox/flox mice and n = 7 for Snai1ΔHSC mice). (c) Serum ALT and AST levels. (d) Representative images of H&E, Masson staining, α-SMA immunohistochemistry staining, and Sirius red staining. Scale bar: 50 μm. (e) Quantification of positive areas in (d). (f) Immunoblotting and quantification of α-SMA. (g) The mRNA levels of collagen-associated genes and pro-inflammatory genes. (h) Representative images and (i) positive signal quantification of Ki67 and p-H3 staining in liver sections. Scale bar: 50 μm. Data are presented as mean ± SEM. P < 0.05 indicates a significant difference. All data were analyzed by a two-tailed Student’s t-test.

      Collectively, these findings demonstrated that the HSC-specific Snai1-deficiency protects against liver fibrosis by alleviating liver injury, HSC activation, collagen deposition, and liver inflammation.

    • Activation of HSCs is one of the critical molecular events driving liver fibrosis[33]. Considering that SNAI1 was specifically increased in fibrotic HSCs, we subsequently examined whether the expression of SNAI1 contributes to HSC activation. TGF-β treatment induced SNAI1 expression in LX2 cells (Fig. 3a), and a progressive increase in Snai1 mRNA level was observed as primary HSCs transitioned from a quiescent to an activated state (Fig. 3b). Transcriptomic and RT-PCR analysis of activated primary HSCs isolated from Snai1flox/flox and Snai1ΔHSC mice both revealed significant reductions in representative pro-fibrotic markers, Acta2 and Col1a1 (Fig. 3b and c). Consistently, other fibrosis-related genes, including Fn1, Timp1, Col4a3, Col7a1, Col11a1, and Mmp8, also decreased in primary HSCs from Snai1ΔHSC mice, suggesting that Snai1 deficiency led to the alleviation of HSC activation. In contrast, the quiescent HSC signatures Lrat and Ecm1 showed no significant difference between the two groups of mice[34] (Fig. 3c). ECM structural constituent and ECM-receptor interaction signaling pathways were remarkably inhibited in Snai1-deleted primary HSCs (Fig. 3d; Supplementary Fig. S3a). Similar findings were obtained by the RNA-seq analysis of LX2 cells transfected with siSNAI1 (Supplementary Fig. S3b and S3c). The regulatory relationship between SNAI1 and fibrotic markers (ACTA2 and COL1A1) was further confirmed by SNAI1 overexpression and silencing in LX2 cells. Overexpression of SNAI1 elevated the mRNA and protein levels of α-SMA and COL1A1, whereas SNAI1 knockdown abolished these effects (Fig. 3e and f; Supplementary Fig. S3d and S3e). SNAI1 is a well-known versatile transcription factor regulating various genes in many physiological and pathological processes, such as EMT (E-cad, N-cad), inflammation (Ccl5 and Cxcl10), and ECM accumulation (Mmp2, Mmp13)[30,35,36]. We therefore generated luciferase reporter constructs containing the ACTA2 or COL1A1 promoter. In LX2 cells, SNAI1 overexpression significantly increased the activity of both promoters under basal conditions and following TGF-β stimulation (Fig. 3g). Because SNAI1 binds E-box motifs within target-gene promoters to regulate transcription[9,10,30], we performed ChIP assays to assess its direct promoter occupancy. The ChIP assays confirmed SNAI1 binding to the ACTA2 and COL1A1 promoters (Fig. 3h). Moreover, SNAI1 increased histone H3 acetylation at K4, K14, and K18 at these promoters, while exerting no significant effect on histone methylation (Fig. 3i).

      Figure 3. 

      Snai1 enhanced the activation of HSCs. (a) Protein level of SNAI1 in LX2 cells treated with 10 μmol·L−1 TGF-β for 48 h. (b) mRNA levels of Snai1, Acta2, and Col1a1 in primary HSCs from Snai1flox/flox and Snai1ΔHSC mice cultured for 0, 5, and 7 d. The P value showed a significant difference by calculating the area under the curve (AUC). (c) Volcano plots of differentially expressed genes (log2FC > 1 and P value < 0.05) between activated primary HSCs isolated from Snai1flox/flox and Snai1ΔHSC mice. (d) Downregulated pathways analyzed by Gene Ontology (GO) pathway enrichment analysis. (e) The protein levels of SNAI1, α-SMA, and COL1A1 in LX2 cells transfected with an empty vector and SNAI1-Flag plasmid (left) or siScramble and siSNAI1, treated with or without TGF-β (right). (f) Gene expression of Acta2 and Col1a1 in LX2 cells. Cells were transfected with siRNA (siScramble and siSNAI1) and treated with 10 μmol·L−1 TGF-β for 48 h. (g) Transcriptional activity of Acta2 and Col1a1 in LX2 cells overexpressing SNAI1 and treated with TGF-β. (h) Representative images of ChIP-PCR analysis confirming the loading of SNAI1 on the promoters of ACTA2 and COL1A1 in LX2 cells. (i) Representative images of ChIP-PCR analysis to determine the recruitment of H3K4Ac, H3K14Ac, and H3K18Ac to the ACTA2 and COL1A1 promoters in LX2 cells with SNAI1 overexpressed. Data are presented as mean ± SEM. P < 0.05 indicates a significant difference. All data were analyzed by a two-tailed Student’s t-test, and data in (g) were analyzed by one-way ANOVA with the Newman–Keuls multiple comparison test.

      In summary, we demonstrated that SNAI1 modulates HSC activation and ECM biosynthesis by directly binding to the ACTA2 and COL1A1 promoters, enhancing the histone acetylation modification, increasing chromatin accessibility, and thereby leading to the transcription of ACTA2 and COL1A1.

    • Accumulating evidence has shown that genetic inhibition of Snai1 has been shown to prevent HSC activation and liver fibrosis, indicating that SNAI1 might be a promising drug target for anti-fibrotic therapy. We have previously designed and synthesized a novel SNAI1 inhibitor named LFW273, which proved to improve atherosclerosis[30] (Fig. 4a). LFW273 enhanced the degradation of SNAI1 by accelerating its ubiquitination (Supplementary Fig. S4a and S4b). Since low concentrations of LFW273 (IC50 = 36.20 μmol·L−1) had no effect on cell viability (Supplementary Fig. S4c), we used 5 or 10 μmol·L−1 LFW273 to treat LX2 cells and primary HSCs for subsequent investigation. As a result, LFW273 significantly reduced the protein level of SNAI1 while having no effect on its transcription (Fig. 4b and c; Supplementary Fig. S4d). TGF-β stimulation increased the expression of classical HSC activation markers α-SMA, type I collagen, and fibronectin 1 (FN1), all of which were dose-dependently suppressed after LFW273 treatment (Fig. 4b−d; Supplementary Fig. S4d and S4e). We also observed reduced transcriptional activity of ACTA2 and COL1A1 after 5 μmol·L−1 LFW273 treatment in LX2 cells, similar to that seen in SNAI1 knockdown cells (Fig. 4e). Additionally, the inhibition of SNAI1 by LFW273 did not cause the compensatory increase but rather a slight reduction of SLUG, which belongs to the same family as SNAI1 (also called SNAI2) and was upregulated by TGF-β (Supplementary Fig. S4f). To further explore the pharmacological mechanism of LFW273 on HSC activation, we performed RNA-sequencing on LFW273- or vehicle-treated primary HSCs. The markedly decreased expression of fibrotic genes such as Acta2, Col1a1, Tgfb2, Tgfb3, Col8a1, Col4a6, Mfap4, and Bmp10 suggested the inhibition of the TGF-β signaling pathway and HSC activation (Fig. 4f). Consistently, vascular smooth muscle contraction, ECM-receptor interaction, and TGF-beta signaling pathway were found decreased in KEGG enrichment analysis in LFW273-treated HSCs (Fig. 4g). In line with the transcriptional changes observed in Snai1-specific knockout HSCs (Supplementary Fig. S3a), KEGG analysis of LFW273-treated primary HSCs revealed upregulation of steroid biosynthesis and insulin resistance pathways (Fig. 4g). BODIPY staining further confirmed increased lipid droplet accumulation in LFW273-treated primary HSCs, a feature associated with a more quiescent-like state compared with cells treated with vehicle[33] (Fig. 4h). Moreover, ChIP assays revealed that SNAI1 binds to the promoter of PPARG, which was reported to be involved in HSC retinyl ester accumulation, and this binding was relieved in SNAI1-overexpressing cells[37,38] (Supplementary Fig. S4g). These findings are consistent with a published report and support that LFW273 promotes lipid accumulation in HSCs through reducing SNAI1 expression and thereby relieving SNAI1-mediated suppression of PPARG transcription. Of note, the suppression of ACTA2 and COL1A1 transcription was abolished in siSNAI1-transfected LX2 cells, suggesting that the efficacy of LFW273 depends on SNAI1 (Fig. 4i; Supplementary Fig. S4h). All the results confirmed that LFW273 treatment protects HSCs from activation, reduces collagen production, and promotes the quiescent state by reducing the transcriptional activation of ACTA2 and COL1A1.

      Figure 4. 

      LFW273, a SNAI1-specific inhibitor, suppressed the activation of HSCs. (a) The construction and molecular weight of LFW273. LX2 cells were treated with 10 μmol·L−1 TGF-β for 12 h, followed by LFW273 at 5 or 10 μmol·L−1 for 48 h. (b) Protein levels of SNAI1, α-SMA (ACTA2) and COL1A1. (c) mRNA expression of SNAI1, COL1A1, and FN1. (d) Immunofluorescent staining with anti-COL1A1 antibody. Scale bar: 20 μm. (e) Transcriptional activity of ACTA2 and COL1A1 in LX2 cells treated with TGF-β and 5 μmol·L−1 LFW273. Primary HSCs activated by FBS for 7 d in vitro and treated with vehicle or LFW273 for 48 h. (f) Volcano plot of differentially expressed pro-fibrotic genes (log2FC > 1 and P value < 0.05). (g) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. (h) Representative images of BODIPY staining (left) and quantification (right). Scale bar: 20 μm. (i) LX2 cells were transfected with siSNAI1 or siScramble and were treated with TGF-β (10 μmol·L−1) for 12 h, followed by 10 μmol·L−1 LFW273 for 48 h. mRNA level of ACTA2 and COL1A1. Data are presented as mean ± SEM. P < 0.05 indicates a significant difference. All data were analyzed by two-tailed Student’s t-test or one-way ANOVA with Dunnett's multiple comparisons test.

    • After examining the function of LFW273 on HSC activation in vitro, we further aimed to evaluate the therapeutic potential of LFW273 in liver fibrosis. Mice were subjected to CCl4 for 4 weeks to induce hepatic fibrosis (Fig. 5a). CCl4 injection resulted in obvious liver injury and collagen deposition (Fig. 5b–d). Compared with fibrotic mice treated with vehicle, LFW273-treated mice showed significantly lower levels of ALT and AST, indicating reduced chemical-induced liver damage (Fig. 5b). Masson staining, Sirius red staining, and COL1A1 immunohistochemical staining showed reduced collagen accumulation following LFW273 administration. In parallel, α-SMA immunohistochemistry indicated reduced HSC activation after LFW273 treatment (Fig. 5c and d). The mRNA levels of fibrotic markers (Acta2, Col1a1, Col1a2, and Timp1) and inflammatory genes (Il6 and Ccl2) were significantly decreased in LFW273-treated mice (Fig. 5e; Supplementary Fig. S5a). We further confirmed the protein levels of α-SMA and type I collagen in liver tissues using immunoblotting (Fig. 5f).

      Figure 5. 

      Pharmacological inhibition of SNAI1 by LFW273 prevented CCl4-induced liver fibrosis in mice. Mice were injected with CCl4 and administered LFW273 for 4 weeks (n = 8 per group). (a) Schematic of the mouse model. (b) Serum ALT and AST. (c) Representative images of H&E, Masson, Sirius red, α-SMA and COL1A1 immunohistochemistry staining. Scale bar: 50 μm. (d) Quantification of positive staining areas in (c). (e) Gene expression of Acta2, Col1a1, Col1a2, Timp1, Il6, and Ccl2. (f) Protein levels of SNAI1, COL1A1, and α-SMA in liver tissues. Data are presented as mean ± SEM. p < 0.05 indicates a significant difference. All data were analyzed by one-way ANOVA with Dunnett's multiple comparisons test.

      To investigate whether LFW273 could reverse pre-existing liver fibrosis, mice received CCl4 injection for 3 weeks, followed by another 4-week LFW273 treatment together with CCl4 injection (Fig. 6a). Hepatic SNAI1 was substantially reduced after LFW273 treatment (Fig. 6b). Compared with mice treated with vehicle, decreased serum ALT and AST, reduced collagen deposition, and lower α-SMA expression were observed in mice that received LFW273 treatment (Fig. 6c−e). mRNA levels of fibrosis-related genes such as Acta2, Col1a1, and Tgfb2 were downregulated after LFW273 treatment (Fig. 6f). Moreover, liver inflammation was relieved in mice with LFW273 administration, as reflected by decreased expression of genes encoding pro-inflammatory cytokines (Tnf, Il6, and Il1b) and chemokines (Ccl2 and Cxcl10) (Fig. 6f). Overall, LFW273 was efficient in preventing and reversing CCl4-induced liver fibrosis.

      Figure 6. 

      LFW273 alleviated the development of liver fibrosis in mice pre-treated with CCl4. Mice were injected with CCl4 for 3 weeks, followed by gavage administration of LFW273 at a dose of 100 mg·kg−1 for an additional 4 weeks (n = 10 per group). (a) Schematic of the mouse model. (b) Immunoblotting of SNAI1. (c) ALT and AST levels in serum. (d) Representative images of H&E, Sirius red, Masson, and α-SMA staining. Scale bar: 50 μm. (e) Quantification of positive staining on liver sections. (f) Gene expressions of Acta2, Col1a1, Col1a2, Timp1, Timp2, Tgfb1, Tgfb2, Tgfb3, and pro-inflammatory genes including Tnf, Il6, Il1b, Ccl2, and Cxcl10 in liver tissues. Data are presented as mean ± SEM. p < 0.05 indicates a significant difference. All data were analyzed by a two-tailed Student’s t-test.

      We further assessed the safety of LFW273 administration. Histological staining of major organs showed minimal toxic effects after the 4-week treatment (Supplementary Fig. S5b). The acute toxicity study revealed no significant differences between mice administered intragastrically with vehicle and 1 g·kg−1 LFW273 (Supplementary Fig. S5c).

      Taken together, our findings demonstrated that the novel small-molecule compound LFW273, which functions as an inhibitor of SNAI1, prevents the development of CCl4-induced liver fibrosis with a superior safety profile.

    • Considerable evidence has revealed that liver fibrosis can be caused by viral hepatitis, ALD, and MASH, and that MASH is becoming the most common liver disease worldwide; however, alleviating liver fibrosis in this context remains challenging[39]. Until now, only resmetirom and semaglutide have been approved by the FDA for MASH therapy and have been reported to attenuate fibrosis progression[5−7]. Therefore, developing novel, effective pharmacotherapies for MASH is urgently needed. Here, we evaluated the anti-fibrotic function of LFW273 and made a comparison with resmetirom in the MCD-induced MASH model with fibrosis. In this model, mice were fed an MCD diet for 2 weeks and then received LFW273 or resmetirom treatment for another 4 weeks, while neither drug affected body weight (Fig. 7a). MCD feeding resulted in significant increases in serum ALT, AST, TBA, γ-GT, DBIL, and TBIL, and both LFW273 and resmetirom treatment improved these liver function abnormalities (Fig. 7b; Supplementary Fig. S6a). H&E and Oil Red O staining showed that SNAI1 inhibition or resmetirom treatment reduced hepatic steatosis (Fig. 7c; Supplementary Fig. S6b). Consistently, serum and hepatic TG and TC levels were also significantly reduced after LFW273 and resmetirom treatment (Fig. 7d; Supplementary Fig. S6c). The improvement in HSC activation and collagen deposition was indicated by reduced positive staining with Masson, Sirius red, and immunohistochemical staining for α-SMA and COL1A1 (Fig. 7c and e); accordingly, the grade of NAS was decreased (Supplementary Fig. S6d). Moreover, the protein levels of α-SMA and COL1A1 were decreased in the livers of LFW273- and resmetirom-treated mice, as detected by immunoblotting (Fig. 7f). We also observed a reduction in hepatic SNAI1 expression in resmetirom-treated mice. This decrease is unlikely to be a direct effect of resmetirom on HSCs, as resmetirom did not affect SNAI1 expression in TGF-β-activated LX2 cells (Supplementary Fig. S6e). Furthermore, fibrosis-related genes (Acta2, Col1a1, Col1a2, Timp2, Tgfb2, and Tgfb3) and inflammatory cytokines and chemokine genes (Tnf, Il1b, Il6, Ccl2, and Ccl5) were downregulated in mice subjected to pharmacological therapy (Fig. 7g and h; Supplementary Fig. S6f).

      Figure 7. 

      MASH-accompanied liver fibrosis was abolished by LFW273 treatment. Mice were fed an MCD diet for 2 weeks, followed by LFW273 and resmetirom administration for an additional 4 weeks (n = 8 for Control; n = 7 for vehicle; n = 6 for LFW273; n = 8 for resmetirom). (a) Body weight. (b) Serum ALT and AST. (c) Representative image of H&E, Masson, Sirius red, and immunohistochemistry staining with anti-α-SMA and anti-COL1A1 antibodies. Scale bar: 50 μm. (d) Hepatic levels of TG and TC. (e) Quantification of positive areas in (c). (f) Protein levels of SNAI1, α-SMA, and COL1A1 in liver tissues. (g) Expression of genes encoding HSC activation and collagen production. (h) Expression of genes related to liver inflammation. Data are presented as mean ± SEM. P < 0.05 indicates a significant difference. All data were analyzed by ordinary one-way ANOVA with Dunnett's multiple comparisons test.

      Collectively, all our results demonstrated that LFW273, a small-molecule inhibitor of SNAI1, is capable of ameliorating MASH-induced liver fibrosis, indicating the potential clinical application of this lead compound LFW273 in MASH treatment.

    • Liver fibrosis is a complication of many chronic liver diseases and remains a major therapeutic challenge[1,2]. Although considerable progress has been made in identifying anti-fibrotic targets and developing candidate drugs, few have been approved for clinical use[40−42]. In this study, we demonstrated that SNAI1, a zinc-finger transcription factor mainly expressed in HSCs, was increased upon HSC activation in patients with liver fibrosis. We further revealed that SNAI1 promoted liver fibrosis progression by directly binding to the promoters of the HSC activation marker genes ACTA2 and COL1A1, and enhanced histone acetylation at H3K4, H3K14, and H3K18 upon HSC activation. Moreover, genetic and pharmacological inhibition of SNAI1 protected mice from CCl4- or MASH-induced liver fibrosis, supporting the idea that SNAI1 might be a promising therapeutic target for anti-fibrotic therapy.

      Most studies on SNAI1 have concentrated on its functions in EMT during tumor progression[9,43,44]. Its pathophysiological roles in non-tumor tissues such as atherosclerosis, renal fibrosis, and muscle regeneration have been recently reported[11,30,45]. Regarding the roles of SNAI1 in liver fibrosis, unlike earlier studies that focused on SNAI1 in hepatocytes[15], our findings demonstrated that the expression of SNAI1 was substantially higher in HSCs than in other cell types, including hepatocytes, KCs, and LSECs. Despite these existing differences, our findings are more consistent with the pathogenesis of liver fibrosis, in which HSCs become activated and transform into myofibroblasts, promoting the production of collagen and ECM. scRNA-sequencing analysis, β-gal/α-SMA co-staining, and immunoblotting of different cells isolated from fibrotic mouse livers confirmed this result. These complementary approaches avoided the false positives and misinterpretation caused by the low specificity of the anti-SNAI1 antibody, providing solid evidence for SNAI1 function in liver fibrosis.

      A recent study reported that the hepatic Snai1 and Snai2 promoted liver regeneration and suppressed liver fibrosis[16], seemingly contradicting our findings. However, that study focused on different cell types from ours, and HSCs play much more direct roles in liver fibrosis. Moreover, their hepatocyte-specific ablation of Snai1 and Snai2 limited the ability to investigate the function of SNAI1 in liver fibrosis. In contrast, using HSC-specific Snai1 deletion mice, our study demonstrates its pro-fibrotic role more directly.

      Liver fibrosis is driven by complex crosstalk between HSCs and surrounding cells[2,46,47]. Activated HSCs secrete cytokines, further influencing immune cells and hepatocytes[48,49]. Consistently, we observed reduced liver inflammation and a slight increase in hepatocyte proliferation in HSC-specific Snai1-deficient mice. Although not all the inflammation-related genes were downregulated, these phenotypes may reflect the crosstalk between HSCs and other cell types.

      In the present study, we demonstrated that LFW273 acts as a specific SNAI1 inhibitor, which decreases the stability of SNAI1[30]. Oral administration of LFW273 protected mice from CCl4 or MASH-induced liver fibrosis, as evidenced by reduced HSC activation, collagen deposition, and inflammation. Although we demonstrated that LFW273 protects HSCs from activation by inhibiting SNAI1 (Fig. 4i), whether its anti-fibrotic efficacy relies solely on SNAI1 in HSCs requires further exploration. Notably, inflammation and endothelial-to-mesenchymal transition (EndMT) of LSECs contribute to liver fibrosis[2,50,51], and SNAI1 has been implicated in both inflammatory chemokine production and EndMT[30,52,53]. LFW273 treatment also suppressed the inflammatory genes in RAW 264.7 mouse macrophages (Supplementary Fig. S7). Therefore, pharmacological inhibition of SNAI1 by LFW273 may improve liver fibrosis not only by acting directly on HSCs, but also potentially by modulating KCs and LSECs.

      A characteristic feature of quiescent HSCs is the abundance of lipid droplets. The loss of lipid droplets acts as a hallmark of HSC activation and is necessary for this critical event. Therefore, maintaining lipid droplet integrity may represent a valid strategy to reduce HSC activation[33]. In this study, we observed that steroid biosynthesis and insulin resistance pathways were significantly activated in primary HSCs after LFW273 treatment, which was associated with reduced HSC activation. Moreover, ChIP assay confirmed the binding of SNAI1 to the PPARG promoter, suggesting that LFW273 promotes maintenance of the lipid-rich quiescent HSCs by relieving PPARG repression. Given that SNAI1 is barely expressed in hepatocytes, the improvement in hepatic steatosis in MASH mice is unlikely to be mediated by a direct SNAI1-PPARG-dependent mechanism. Instead, these effects may result from indirect crosstalk between HSCs, immune cells (such as KCs), and hepatocytes, as inflammation is known to promote hepatic lipid accumulation[54,55]. Nevertheless, the mechanism by which SNAI1 inhibitor affects hepatic steatosis remains to be investigated to further elucidate its potential for anti-MASH therapy.

      Evidence shows that the prevalence of MASH-induced fibrosis has progressively risen[39], with only two drugs, resmetirom and semaglutide, approved by the FDA for MASH therapy[5−7]. In this study, we chose resmetirom as the positive control. Although resmetirom treatment reduced SNAI1 levels in fibrotic mouse livers (Fig. 7e), it did not suppress the expression of SNAI1 in HSCs (Supplementary Fig. S6e), which is consistent with resmetirom improving liver fibrosis by targeting THRb in hepatocytes and affecting HSCs indirectly via intercellular crosstalk. In contrast, LFW273 treatment acts more directly on HSCs and thereby abolishes HSC activation and collagen accumulation.

      However, it should be noted that MCD-induced MASH, which causes decreased body weight and lacks insulin resistance, does not recapitulate the metabolic features of clinical MASH, despite its wide use for rapid fibrosis establishment[56]. Long-term MASH models, such as those induced by GAN diet or CDAHFD, are more suitable for phenocopying clinical MASH. Nevertheless, the MCD-induced MASH-associated fibrosis model remains a valuable tool for the preliminary evaluation of anti-fibrotic drugs. Regarding LFW273, despite the acceptable oral bioavailability (~50%), its relatively high effective dose and short plasma t1/2 (~2.85 h) suggest the need for further structural modification and optimization to improve its pharmacokinetic properties. Once optimized candidates are identified, their efficacy and safety will be systematically evaluated in long-term MASH models to further validate their anti-fibrotic potential.

    • Collectively, our study delineated the pro-fibrotic function of SNAI1 in HSCs, and SNAI1 increases the transcription of ACTA2 and COL1A1 via epigenetic regulation of their promoters to accelerate liver fibrosis. More importantly, genetic inhibition of Snai1 and pharmacological inhibition by LFW273 effectively protected mice from CCl4-induced liver fibrosis. LFW273 treatment also demonstrated remarkable effects in MCD-induced fibrosis, comparable to those of resmetirom treatment. These findings indicate that SNAI1 might be a promising drug target for liver fibrosis therapy, and that LFW273 could serve as a potential lead compound for further optimization.

      • All procedures were reviewed and pre-approved by the Institutional Animal Care and Use Committee of China Pharmaceutical University (YSL-202504067, approval date: 2025−4−14). The research followed the 'Replacement, Reduction, and Refinement' principles to minimize harm to animals. This article provides details on the housing conditions, care, and pain management for the animals, ensuring that the impact on the animals is minimized during the experiment.

      • The authors confirm their contributions to the paper as follows: study conception and design: Wu ZQ, Fu R, Liu J; data collection: Pan C, Zhang XZ, Xu XW; analysis and interpretation of results: Pan C, Zeng ZL, Weiss SJ; draft manuscript preparation: Pan C, Wu ZQ, Fu R. All authors reviewed the results and approved the final version of the manuscript.

      • RNA-seq data have been deposited in GEO and are publicly available under accession number GSE329196. All data reported in this paper are available from the corresponding author upon reasonable request.

      • The authors have no conflict of interest to declare.

      • #Authors contributed equally: Chuyue Pan, Xu-zhe Zhang, Xiao-wen Xu

      • Copyright: © 2026 by the author(s). Published by Maximum Academic Press on behalf of China Pharmaceutical University. This article is an open access article distributed under Creative Commons Attribution License (CC BY 4.0), visit https://creativecommons.org/licenses/by/4.0/.
    Figure (7)  References (56)
  • About this article
    Cite this article
    Pan C, Zhang XZ, Xu XW, Zeng ZL, Weiss SJ, et al. 2026. Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice. Targetome 2(6): e064 doi: 10.48130/targetome-0026-0060
    Pan C, Zhang XZ, Xu XW, Zeng ZL, Weiss SJ, et al. 2026. Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice. Targetome 2(6): e064 doi: 10.48130/targetome-0026-0060

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return